Literature DB >> 23154086

Molecular pathways: regulation of metabolism by RB.

Brian F Clem1, Jason Chesney.   

Abstract

The discovery of the retinoblastoma (RB-1) gene as a tumor suppressor that is disrupted in a majority of human cancers either via direct or indirect genetic alterations has resulted in increased interest in its functions and downstream effectors. Although the canonical pathway that links this tumor suppressor to human cancers details its interaction with the E2F transcription factors and cell-cycle progression, recent studies have shown an essential role for RB-1 in the suppression of glycolytic and glutaminolytic metabolism. Characterization of the precise metabolic transporters and enzymes suppressed by the RB-E2F axis should enable the identification of small molecule antagonists that have selective and potent antitumor properties. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23154086     DOI: 10.1158/1078-0432.CCR-11-3164

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

Review 1.  Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.

Authors:  Rizwan Haq; David E Fisher; Hans R Widlund
Journal:  Clin Cancer Res       Date:  2014-03-07       Impact factor: 12.531

2.  Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.

Authors:  Inan Olmez; Breanna Brenneman; Aizhen Xiao; Vlad Serbulea; Mouadh Benamar; Ying Zhang; Laryssa Manigat; Tarek Abbas; Jeongwu Lee; Ichiro Nakano; Jakub Godlewski; Agnieszka Bronisz; Roger Abounader; Norbert Leitinger; Benjamin Purow
Journal:  Clin Cancer Res       Date:  2017-08-16       Impact factor: 12.531

3.  MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition.

Authors:  Lina S Schneider; Melanie Ulrich; Thorsten Lehr; Dirk Menche; Rolf Müller; Karin von Schwarzenberg
Journal:  Mol Oncol       Date:  2016-04-27       Impact factor: 6.603

4.  Deficiencies in Cellular Processes Modulated by the Retinoblastoma Protein Do Not Account for Reduced Human Cytomegalovirus Replication in Its Absence.

Authors:  Halena R VanDeusen; Robert F Kalejta
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

Review 5.  Clinical development of cancer therapeutics that target metabolism.

Authors:  B F Clem; J O'Neal; A C Klarer; S Telang; J Chesney
Journal:  QJM       Date:  2015-10-01

6.  Disruption of retinoblastoma protein expression in the intestinal epithelium impairs lipid absorption.

Authors:  Pamela M Choi; Jun Guo; Christopher R Erwin; Wambui S Wandu; Jennifer A Leinicke; Yan Xie; Nicholas O Davidson; Brad W Warner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

7.  Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.

Authors:  Jorge Franco; Uthra Balaji; Elizaveta Freinkman; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Cell Rep       Date:  2016-01-21       Impact factor: 9.423

Review 8.  Retinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategies.

Authors:  Susumu Kohno; Shunsuke Kitajima; Nobunari Sasaki; Chiaki Takahashi
Journal:  World J Stem Cells       Date:  2016-04-26       Impact factor: 5.326

9.  Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.

Authors:  Michael L Nickerson; Garrett M Dancik; Kate M Im; Michael G Edwards; Sevilay Turan; Joseph Brown; Christina Ruiz-Rodriguez; Charles Owens; James C Costello; Guangwu Guo; Shirley X Tsang; Yingrui Li; Quan Zhou; Zhiming Cai; Lee E Moore; M Scott Lucia; Michael Dean; Dan Theodorescu
Journal:  Clin Cancer Res       Date:  2014-09-15       Impact factor: 12.531

10.  RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease.

Authors:  Amy C Mandigo; Wei Yuan; Kexin Xu; Peter Gallagher; Angel Pang; Yi Fang Guan; Ayesha A Shafi; Chellappagounder Thangavel; Beshara Sheehan; Denisa Bogdan; Alec Paschalis; Jennifer J McCann; Talya S Laufer; Nicolas Gordon; Irina A Vasilevskaya; Emanuela Dylgjeri; Saswati N Chand; Matthew J Schiewer; Josep Domingo-Domenech; Robert B Den; Jeff Holst; Peter A McCue; Johann S de Bono; Christopher McNair; Karen E Knudsen
Journal:  Cancer Discov       Date:  2021-04-20       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.